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1. Introduction 
Evidence based medicine (EBM) is becoming a cornerstone in the establishment of practical 
guidelines and is nowadays part of the process of decision making in medicine (Woolf 2000). 
In evidence based medicine, decision making is based on relevant clinical trials ranked by 
their relevance and validity according to established criteria. Indeed, well designed 
randomized controlled trials (RCTs) are considered the "gold standard". However, since 
hematological disorders such as acute leukemia are rare, RCTs with a large enough sample 
size are difficult to conduct.  
Systematic reviews use a preplanned, explicit methodology to answer a predefined question 
and evaluate the benefit and harm of healthcare interventions. Meta-analyses quantitatively 
assemble results from RCTs to increase power when individual studies are too small to 
detect a statistically significant effect (Gale and Lazarus 2011). The quality of a systematic 
review reflects the quality of its included studies. Potential sources of bias are heterogeneity 
between the RCTs included, publication bias and difficulties in accessing data from the 
original clinical trials. 
In this chapter we attempted to assemble the evidence on the available meta-analyses 
analyzing the data in acute myeloid leukemia (AML) and acute lymphoblastic leukemia 
(ALL) patients. In certain domains, when no meta-analyses were identified, a literature 
search was performed and, if applicable, suggestions for future studies were made. 
2. Methods  
We searched The Cochrane and MEDLINE databases for systematic reviews. In Pubmed we 
crossed MeSH terms for 'acute myeloid leukemia' or 'acute lymphoblastic leukemia' with 
Clinical Queries to limit the search for systematic reviews.  
We included systematic reviews of RCTs (with or without meta-analyses) assessing the 
effect of different chemotherapy regimens and supportive care on overall survival of 
patients with acute leukemia. We included the use of these treatment options in the 
following clinical settings: remission induction, post remission (consolidation) including 
autologous and allogeneic stem cell transplantation and maintenance.  
We assessed the risk of bias in the systematic reviews by the following domains: use of 
explicit inclusion/exclusion criteria and a predefined protocol; comprehensive search; 
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whether selection bias was avoided; assessment of risk of bias of original trials; correct 
statistical methods to pool the data. Assessment of risk of bias in each of the systematic 
reviews based on the AMSTAR protocol is summarized in tables 1-2 and 4 (Liberati, et al 
2009, Oxman and Guyatt 1991, Shea, et al 2007, Shea, et al 2009). 
For the evaluation of prospective comparative trials in the transplantation field, we searched 
for meta-analyses including genetically randomized trials. These trials were defined by 
patient allocation to an intervention on the basis of sibling donor availability (donor group 
versus no-donor group) and were evaluated for potential bias as previously discussed (Ram, 
et al 2011).  
3. An overview of systematic reviews in acute myeloid leukemia 
Survival of AML patients has constantly been increasing from about 5-10% in 1975 to about 
25% of diagnosed patients according to SEER data (1975-2007) in US population. This 
progress is the result of the progress in supportive care enabling treatment with intensive 
chemotherapy to induce remission and the use of allogeneic hematopoietic cell 
transplantation (HCT), as well as the use of prognostic factors in clinical decision making. 
For the majority of patients with AML this disease still has grave consequences. Our 
understanding of cytogenetic and molecular factors in the pathogenesis and the prognosis of 
patients with AML has evolved tremendously during the last decade. Still our ability to cure 
has remained unsatisfactory. 
Treatment of AML with curative intent is generally divided into remission induction and 
post remission (also referred to as consolidation) courses (Dohner, et al 2010). Management 
of patients with AML depends mainly on their age, their response to therapy and the 
cytogenetic and molecular factors of the leukemic clone, stratifying patients into favorable, 
standard and unfavorable risk groups.  
We herein reviewed the results of systematic reviews assessing chemotherapy for patients 
with AML. For each systematic review we evaluated the methodological quality using the 
AMSTAR assessment tool (Table 1). 
3.1 Induction therapy 
For more than 3 decades remission induction treatment consists of anthracyclines 
administered for 3 days and cytarabine given at a dose of 100-200 mg/m2 in continuous 
infusion for 7 days. Efforts to improve response rate and survival of patients with AML 
included the addition of other chemotherapeutic drugs to the standard induction regimen, 
using different types and doses of anthracyclines, as well as different doses of cytarabine. 
3.1.1 Does the type of anthracycline affect overall survival of adult patients with AML? 
A systematic collaborative overview of individual patient data of RCTs that compared an 
idarubicin-based induction regimen with a different anthracycline-based regimen included 
trials from 1984 to 1993 including 1898 patients (AML Collaborative Group, 1998). 
Compared to daunorubicin, idarubicin improved remission rate (53% vs. 62%, respectively, 
p = 0.002) and overall survival (14% odds reduction, p = 0.03), however disease free survival 
(DFS) did not differ significantly (15% odds reduction, p=0.07). This overview fulfilled 4 of 
11 criteria of the AMSTAR tool.  
Since the publication of this systematic review new data has accumulated (Mandelli, et al 
2009, Rowe, et al 2004).  
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3.1.2 Does the dose of anthracyclines during induction have an effect on survival? 
Historically, the conventional induction anthracycline dose was the equivalent of 
daunorubicin 45-50 mg/m2 daily given for 3 days. Large case series and observational 
studies supported a dose escalation to 60 mg/m2. It remained questionable if the dose 
response curve has reached a plateau and whether the dose amplification benefit can be 
confirmed in RCTs. A few RCTs evaluated various dosages of anthracyclines. No published 
systematic review has summarized their findings so far. 
Two RCTs evaluated dose intensification of anthracyclines (Fernandez, et al 2009, 
Lowenberg, et al 2009). Patients <60 years old treated with 90 mg/m2 of daunorubicin, as 
compared with the standard 45 mg/m2, achieved a higher rate of complete remission (CR) 
(70.6% vs. 57.3%; P<0.001) and a better overall survival (P=0.003) (Lowenberg, et al 2009). In 
another trial, >60 year-old patients treated with higher doses of daunorubicin, i.e. 90 mg/m2 
as compared to 45 mg/m2 daily, for 3 days, had higher CR rates (64% for the high dose vs. 
54% for the standard dose; P=0.002) (Pautas, et al 2010). There was no significant difference 
between the two groups in the incidence of hematological adverse events, 30-day mortality 
(11% and 12% in the 2 groups, respectively), or the incidence of adverse events (P=0.08). An 
overall survival benefit was demonstrated only in 2 subgroups: patients aged 60 to 65 years, 
and those with favorable cytogenetics. Paustas et al. compared 3-days of daunorubicin 80 
mg/m2/day with 3 or 4-days of idarubicin 12 mg/m2/day in 468 patients aged 50 to 70 
years. While a statistically significant higher rate of CR was demonstrated in patients treated 
with idarubicin (P = .04), there were no significant differences in the other outcomes.  
Thus, conventional dose for remission induction in adult patients < 60 years with AML 
should be between 60 to 90 mg/m2/day. There is no clear benefit for higher doses (90 
mg/m2/day) of daunorubicin compared to 45 mg/m2 daily in adults >65 years. 
3.1.3 Do higher doses of cytarabine during remission induction treatment improve 
survival? 
Kern and Estey reviewed the literature to examine the effect of high dose cytarabine (≥1000 
mg/m2/dose) in induction therapy compared with standard dose (100-200 mg/m2/day) 
cytarabine (Kern and Estey 2006). The search yielded 3 trials, evaluating 1691 adult AML 
patients < 60 years. There was no difference between high dose and standard dose 
cytarabine with regard to CR rate (relative risk 1.00; 95% CI 0.92 to 1.10) or early death rate 
(RR 1.53; 95% CI 0.84 to 2.78, random-effects model). However, 4-year overall survival was 
better in patients given high dose cytarabine (weighted mean difference, 6.211; 95% CI, 2.701 
to 9.721). In this meta-analysis time to event data was analyzed as continuous data, the 
assumptions made for converting median to mean and their variance to standard deviation 
were not described, and weighted mean difference was used to pool results. This review 
fulfilled 7 of 11 criteria of the AMSTAR criteria. 
3.2 Post remission therapy 
3.2.1 What is the role of transplantation in patients with AML? 
3.2.1.1 Autologous hematopoietic cell transplantation  
Four systematic reviews evaluated the effect of autologous hematopoietic cell 
transplantation (HCT) in first CR (Ashfaq, et al 2010, Levi, et al 2004, Nathan, et al 2004, 
Wang, et al 2010). 
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Nathan et al. compared the efficacy of autologous HCT with chemotherapy (or no further 
treatment) in patients aged 15 to 55 years (Nathan, et al 2004). Their search yielded 6 trials 
including 1044 patients. Patients who underwent autologous HCT had a better DFS 
(probabilities ratio of 1.24, 95% CI 1.06 to 1.44) with similar long term mortality rate (RR 
1.01, 95% CI 0.89 to 1.15). This review fulfilled 9 of 11 criteria of the AMSTAR tool. Levi et al 
performed a systematic review on the same question with similar findings (Levi, et al 2004). 
A more recent systematic review included 12 RCTs (Wang, et al 2010). Patients treated with 
autologous HCT had lower relapse rate,better DFS, but no overall survival benefit probably 
because of higher treatment related mortality. Of note, at present, transplant related 
mortality is lower than the estimated 4% reported in these systematic reviews.  
3.2.1.2 Allogeneic hematopoietic cell transplantation  
Eight reviews and meta-analyses were identified but only three of them were systematic and 
comprehensive (Ashfaq, et al 2010, Hubel, et al 2011, Koreth, et al 2009). Koreth et al. performed 
a systematic review comparing allogeneic HCT with conventional consolidation chemotherapy 
or autologous HCT (Koreth, et al 2009). Patients allocated to the allogeneic HCT arm had an 
overall survival benefit (HR 0.90 95% CI 0.82 to 0.97, 15 trials), and relapse free survival (HR 
0.80 95% CI, 0.74 to 0.86, 18 trials). In an analysis stratified according to the cytogenetic risk 
groups, only intermediate and poor risk AML patients allocated to the allogeneic HCT arm 
had improved overall survival, while favorable risk patients had similar overall survival in 
both allocated arms. This review fulfilled 10 of 11 criteria of the AMSTAR tool.  
Another comprehensive systematic review (without a quantitative summary) was done 
through the National Institute for Health Research Health Technology Assessment (HTA) 
program in UK (Ashfaq, et al 2010). The results and conclusions of this very detailed review 
were consistent with those of the previous ones. Other systematic reviews were published 
earlier and were not as comprehensive (Oliansky, et al 2008, Schlenk, et al 2004, Visani, et al 
2006, Yanada, et al 2005). 
3.3 Consolidation – dose intensity of cytarabine  
A systematic overview without a quantitative analysis of chemotherapy for patients with AML 
was conducted by The Swedish Council of Technology Assessment in Health Care (Kimby, et 
al 2001). In one trial consolidation was compared to no further treatment. This trial was closed 
early due to inferior remission duration in the latter group. In all the trials comparing high 
dose cytarabine to standard dose or maintenance therapy, high dose cytarabine was shown to 
be superior to the comparator, though overall survival advantage was not consistently shown. 
Consolidation with high dose cytarabine seemed to be of value mainly for patients with core 
binding factor AML and in younger patients, due to a high mortality rate in patients older 
than 60 years. This overview fulfilled 1 of 10 criteria of the AMSTAR tool. 
3.4 Maintenance therapy instead of consolidation chemotherapy 
This question was reviewed by Kimby et al. who found limited data to indicate that post-
remission maintenance therapy with long-term attenuated chemotherapy can prolong 
remission duration compared to no further therapy (Kimby, et al 2001). However, the data in 
support of these conclusions are sparse and effect on survival was not shown. 
3.5 Role of azacitidine  
Azacitidine was not exclusively assessed in AML patients but rather analyzed in a pooled 
myelodysplasia/AML group of patients (20%- 30% blasts, defined by the WHO as AML) 
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The AML collaborative 
group 1998 
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2004 
Levi 
2004 
Yanada 
2005 
Was an ‘a priori’ design provided?  Yes Yes Yes Yes Yes 
Was there duplicate study selection and data 
extraction? 
Not reported Yes Yes Yes No  
Was a comprehensive literature search performed?  No Yes Yes No No 
Was the status of publication used as an inclusion 
criterion? (i.e. grey literature was included) 
Yes Yes No No No 
Was a list of studies (included and excluded) 
provided?  
No No Yes No Yes 
Were the characteristics of the included studies 
provided? 
Yes Yes Yes Yes Yes 
Was the scientific quality of the included studies 
assessed and documented? 
Yes Yes Yes Yes Not 
reported
Was the scientific quality of the included studies used 
appropriately in formulating conclusions? 
No No No Yes No 
Were the methods used to combine the findings of 
studies appropriate?  
Yes No, analyzed survival 
data as a continuous 
variable 
Unclear Yes Yes 
Was the likelihood of publication bias assessed?  No No Yes No Yes 
Were potential conflicts of interest included?  No No Yes No No 
Total 5 6 8-9 6 5 
Table 1. Assessment of risk of bias using AMSTAR criteria in systematic reviews in the field of AML 
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(Edlin, et al 2010). This RCT shows an overall survival benefit for azacytidine compared to 
best supportive care, low dose cytarabine, or intensive chemotherapy. Two RCTs that 
evaluated the effect of azacytidine in patients with high risk MDS (including patients with 
20%- 30% blasts) showed improved time to transformation or death in patients given 
azacytidine (Fenaux, et al 2009, Silverman, et al 2002). 
Azacytidine was also given as part of post remission chemotherapy: in the MRC AML 9 
trial, patients given the azacitidine-chemotherapy arm as consolidation had fewer relapses 
comparedto patients given only chemotherapy (p = 0.003), but a higher treatment related 
mortality (4.5% vs. 0%), without a statistically significant improved long term survival 
(Rees, et al 1996). 
In another trial,  patients were randomized to post remission consolidation with different 
chemotherapy regimens: standard dose cytarabine-daunorubicin vs. the same treatment 
followed by amsacrine and azacytidine vs. thioguanine and standard dose cytarabine-
daunorubicin (Volger, et al 1995). The 5-year DFS was 38%, 31%, and 27% (p<0.05), 
respectively. 
4. Acute promyelocytic leukemia  
Acute promyelocytic leukemia (APL) is usually characterized by a specific gene 
rearrangement and the generation of the PML-RARα fusion transcript which results from a 
translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid 
(ATRA) and anthracycline-based chemotherapy results in cure in 70-80% of patients. 
Two systematic reviews evaluated the first line treatment of patients with APL (Xu, et al 
2009a, Xu, et al 2009b). 
The first one includes 7 RCTs (392 patients) comparing ATRA plus arsenic trioxide to other 
treatments. Compared with arsenic trioxide monotherapy, arsenic trioxide plus ATRA 
affected neither CR or DFS rates nor mortality of relapsed APL patients. Arsenic trioxide 
plus ATRA improved CR rate, DFS, mortality rate and adverse reactions compared to the 
same regimen including also chemotherapy. The review fulfilled 6 of 11 criteria of the 
AMSTAR tool. 
A systematic review and meta-analysis including 5 randomized controlled trials (328 
patients) compared ATRA plus arsenic trioxide regimen with ATRA monotherapy in 
patients with APL showed an improved 2-year DFS rate in the group treated with ATRA 
arsenic trioxide. 
5. An overview of systematic reviews in acute lymphoblastic leukemia 
Acute lymphobIastic leukemia (ALL) is the most common acute leukemia in children, while  
the incidence is much lower in adults (National Cancer Institute. SEER Cancer Statistics 
Review Available at: http://seer.cancer.gov/csr/1975_2006). The outcome of pediatric ALL 
patients has evolved from an overall survival of less than 10% in the 1960s to approximately 
80% at present (Pui, et al 2008). However, adult patients have a less optimistic prognosis. 
While the remission rate reaches 90%, the survival rate is only 40%-50% (Fielding 2008).  
ALL patients are stratified and treated according to algorithms that integrate the presenting 
features, leukemia features and early response to therapy (Faderl, et al 2003); However  the 
classification to standard and poor risk disease varies among the major studies conducted in 
adult ALL patients (Hoelzer, et al 1988, Kantarjian, et al 2004, Lazarus, et al 2006, Le, et al 
2006, Rowe, et al 2005, Ram, et al 2010). 
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Treatment of adult ALL patients usually consists of remission induction and 
consolidation/intensification phases followed by either HCT or maintenance therapy. 
As stated above, because the disease is relatively rare in adults, much of the knowledge and 
protocols have been adopted from pediatric regimens. Although we aim to focus on adult 
population, a portion of the data is based on evidence from pediatric trials.  
For each systematic review we evaluated the methodological quality using the AMSTAR 
assessment tool (table 2). 
5.1 Is there a specific induction regimen which is better? 
Different groups use various induction regimens, which have not been compared head to head 
(Gokbuget and Hoelzer 2009, Kantarjian, et al 2004, Larson, et al 1995, Linker, et al 2002, 
Thomas, et al 2004b). In adult patients, the use of growth factors such as granulocyte colony-
stimulating factor that accelerate hematopoietic recovery has greatly improved the success rate 
of ALL therapy (Kantarjian, et al 2004) and will be reviewed in a different part of this chapter.  
One individual patient data meta-analysis examined the role of incorporating different 
types of anthracycines into pediatric induction regimens (CALLCG, 2009) and identified  4 
trials recruiting 958 patients. They found that there was a borderline significant reduction in 
bone marrow leukemia relapse rate (OR 0.77, 95% CI 0.60 to 1.00; p=0.05) among patients 
treated with anthracyclines compared to those not, though there was no difference in non-
bone marrow leukemia relapse rate (OR 0.88, 95% CI 0.63 to 1.25; p=0.5). The reduction in 
relapse rate translated into improved relapse free survival (OR 0.81; 95% CI, 0.66 to 1.00; 
p=0.05). However, event free survival (EFS) and overall survival were similar between the 
two groups. No significant differences in outcomes were demonstrated when different 
anthracyclines or when different adninistration schedules were compared. As this meta-
analysis has been solely conducted in a pediatric population, results might not be applicable 
for adult patients. This systematic review fulfilled 5 of 11 criteria of the AMSTAR tool. 
5.2 What is the role of pediatric inspired regimens for adult patients, mainly for the 
group of adolescents and young adults? 
Several recent studies comparing the outcome of adolescents and young adults (AYAs) up 
to the age of 45 years, treated with pediatric versus adult protocols, demonstrated improved 
survival for AYAs who were treated by pediatric groups (Boissel, et al 2003, Ramanujachar, 
et al 2007, Stock, et al 2008). All are non-randomized trials and are therefore prone to 
significant bias. Thus, these trials are difficult to interpret because of the wide spectrum of 
patients' age, the small number of patients, the variations in the regimens utilized and the 
varying application of HCT in different studies. Recently our group completed a systematic 
review and meta analysis of all published comparative studies. We showed that up to the 
age of 20 years, pediatric inspired regimens are superior to conveintional afults 
chemotherapy ( Ram, et al 2011). Currently there are several groups conducting prospective 
trials (e.g., US AALL0232) to further elucidate which is the best treatment for AYAs. Only 
then, solid conclusions to tailor the best treatment for AYAs should be drawn.    
5.3 What is the role of thyrosine kinase inhibitors in the treatment of Philadelphia 
positive ALL? 
Philadelphia positive ALL is a disease with a historically dismal prognosis in which HCT 
provided the only chance for cure (Fielding and Goldstone 2008). Recently, the introduction of 
tyrosine kinase inhibitors (TKIs) has opened wide new perspectives of how to treat these 
patients (Thomas, et al 2004a). We were not able to identify systematic reviews assessing the 
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2006 
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Health Teq 
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CALLCG, 
Lancet 1996 
Was an ‘a priori’ design provided?  Yes Yes Yes Yes Yes Yes Yes Yes
Was there duplicate study selection and data 
extraction?  
No No Yes Yes No No No No No No 
Was a comprehensive literature search performed?  Yes Yes Yes Yes Yes Yes Yes 
Was the status of publication used as an inclusion 
criterion? (i.e. gray literature was included) 
No Yes Yes No No No No No No No 
Was a list of studies (included and excluded) 
provided?  
No Yes No Yes No Yes No No Yes
Were the characteristics of the included studies 
provided?  
Yes Yes Yes Yes Yes Yes No 
Was the scientific quality of the included studies 
assessed and documented? 
No Yes Yes Yes Yes No No Yes
Was the scientific quality of the included studies 
used appropriately in formulating conclusions?  
No Yes Yes Yes Yes No No No No No 
Were the methods used to combine the findings of 
studies appropriate?  
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Was the likelihood of publication bias assessed? No Yes No Yes No No No 
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role of the different tyrosine kinase inhibitors. Prospective comparison, for example, by using 
genetic randomization based on donor availability along with intention-to-treat analysis, is 
necessary to draw conclusions on the clinical utility of allogeneic HCT for these patients.  
5.4 What is the role of allogeneic HCT in first CR? 
Allogeneic HCT provides a potential curative approach for patients with ALL, mainly 
through the anti-leukemic effect of the graft. Nonetheless, the relatively high non-relapse 
mortality compared to other treatment options limits the widespread use of this approach 
(Hahn, et al 2006, Ram, et al 2011). 
As stated in the Methods section, the preferred way to assess the role of allogeneic HCT is to 
use a genetic randomization design, allocating patients with a matched sibling donor and 
those lacking sibling donor to the donor/transplantation arm and the no-donor/alternative 
treatment arm, respectively (Ram, et al 2011).  
Five systematic reviews were conducted (Ashfaq, et al 2010, Hahn, et al 2006, Orsi et al 2007, 
Ram, et al 2010, Yanada et al 2006), 3 out of which included also a meta analysis (Orsi et al 
2007, Ram, et al 2010, Yanada et al 2006). All three meta-analyses showed that overall, for 
ALL patients achieving first CR, allogeneic HCT carries a survival benefit compared to the 
other options. While all 3 meta-analyses used similar search criteria, the strict intention to 
treat (ITT) inclusion criteria were different. Moreover, the two largest trials in the field 
(Cornelissen et al 2009, Goldstone et al 2008) were included only in the most recently 
published  meta-analysis only (Ram, et al 2010). This meta-analysis included 10 genetically 
trials, randomizing 2,600 patients for the main comparison of allogeneic HCT vs. other 
treatments, with only seven trials, randomizing 1,863 patients, following strict ITT criteria 
(table 2). In this meta-analysis, survival benefit was statistically significant for the standard-
risk patients (RR for all-cause mortality 0.80, 95% CI 0.68–0.94), while for the high-risk it it 
was not (RR 0.88, 95% CI 0.76–1.01) (Ram, et al 2010). As expected, there was a significant 
increase in non-relapse mortality in the allogeneic HCT arm (RR 2.99; 95% CI, 1.37-6.53) and 
a significant decrease in the relapse rate (RR 0.52; 95% CI, 0.33-0.83). This systematic review 
fulfilled 10 of 11 criteria of the AMSTAR tool. 
Although a systematic review published by Yanada et al showed a similar survival 
advantage in favor of the donor group (HR 1.29, 95% CI 1.02 to 1.63, p = 0.037), superiority 
could be demonstrated for the high-risk patients subgroup only (HR 1.42, 95% CI 1.06 to 
1.90; p = 0.019). This systematic review fulfilled 8 of 11 criteria of the AMSTAR tool.  
The difference between the two meta-analyses might stem from two main causes: The first is 
the inclusion of the two recent large trials in the last meta-analysis only (Cornelissen et al 
2009, Goldstone et al 2008) and the second from the different methodologies and inclusion 
criteria used in the various studies (with more emphasis on strict ITT methodology in the 
recently published meta-analysis).  
Orsi et al. conducted an individual patient meta-analysis of four trials (Hunault et al., 2004, 
Labar et al 2004, Ribera et al 2005, Thomas, et al 2004b). They also showed survival benefit for 
the donor group (mean EFS was 5.88 years in the donor group and 4.88 years in the no-
donor group) with survival rate of 44.2% (± 2.9%) at 7 years in the donor group and 31.6%  
(± 2.2%) in the non-donor group, log-rank test p = 0.011. Performance of allogeneic HCT in 
first CR was found to be cost effective. This systematic review fulfilled 9 of 11 criteria of the 
AMSTAR tool. 
To summarize, all meta-analyses suggest overall survival benefit for patients undergoing a 
matched donor allogeneic HCT in first CR when compared to other modalities. By drawing 
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firm conclusions based on strict ITT trials it is suggested that allogeneic HCT may be more 
effective for the standard risk group.  
5.5 Is there a role for autologous HCT in first CR? 
We identified three systematic reviews that reported on the comparison between post 
remission autologous HCT and maintenance chemotherapy (Ashfaq, et al 2010, Hahn, et al 
2006, Ram, et al 2010). One of them also performed a meta-analysis of the available RCTs. 
Both Hahn et al. and Ashfaq et al. concluded that both autologous HCT and maintenance 
chemotherapy yield a similar outcome (Ashfaq, et al 2010, Hahn, et al 2006). They also 
suggested that autologous HCT might be a superior option for high risk patients. In the 
meta-analysis performed by our group (Ram, et al 2010), five conventionally randomized 
trials enrolling 963 patients were identified. Similar to previous systematic reviews, survival 
was comparable between the two arms (RR 1.02, 95%CI, 0.88 to 1.19) for both standard and 
high risk patients. However there was a significant increase in non-relapse mortality in the 
autologous HCT arm (RR 1.77; 95% CI, 1.12 to 2.8), though no statistically significant 
difference was demonstrated in the relapse risk (RR 0.92; 95% CI, 0.73-1.15).  
 
 Yanada, Cancer 2006 Orsi, BMT 2007 Ram, Cancer 2010 
Bernasconi 1992*   + 
Sebban 1994* + + + 
Attal 1995*   + 
Takeuchi 2002* +  + 
Dombret 2002,Thomas 2004* + + + 
Labar 2004# +  + 
Hunault 2004# + + + 
Ribera 2005* + + + 
Vey 2006*   + 
Cornelissen 2008#   + 
Goldstone 2008*   + 
Fielding, 2009*   + 
*True ITT trial    #Not strictly ITT trial – Reasons for the inability to perform ITT analysis: Labar,2004- 
inclusion of patients with no siblings in the non-donor arm; Hunault, 2004- inclusion of patients>50 
years in the non-donor group ; Cornelissen,2008- inclusion of patients who underwent matched 
unrelated donor transplantation in the nondonor study arm 
Table 3. Comparisons between 3 meta-analyses assessing the role of allogeneic 
hematopoietic cell transplantation in first complete remission  
5.6 Which is the best maintenance therapy? 
The post remission high relapse rate of adult ALL patients has encouraged  the exploration 
of various post-remission modalities. The optimal type and duration of maintenance 
therapy and the value of further intensification are still debated.  
We identified 3 relevant systematic reviews (CALLCG et al 1996, Eden, et al 2010, Escherich, 
et al 2011), reporting on pediatric patients.  
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The first, evaluating the impact of duration and intensity of the different maintenance 
regimens, included 16 trials, randomizing 746 patients (CALLCG et al., 1996) showed that 
maintenance treatment administered for up to 3 years was associated with a  significantly 
lower relapse rate albeit a similar  rate of death from leukemia. Of note, maintenance 
duration beyond 3 years did not yield any superiority . More intensive regimens were 
associated with significantly fewer relapse events and with prolonged survival (absolute 
difference in survival of about 3% at 5 years and of 4% at 8 years). This systematic review 
fulfilled 3 of 11 criteria of the AMSTAR tool. 
The second systematic review evaluated the addition of steroids plus vincristine pulses 
during the maintenance period (Eden, et al). In an individual patient meta-analysis 
vincristine-prednisone pulses were shown to improves EFS (70.1% vs. 62% at 5 years; OR 
0.71, 95% CI  0.61 to 0.84; p = 0.00004), while vincristine - dexamethasone pulses did not 
have this effect (80.9% vs. 79.9% at 5 year; OR 0.94; 95% CI, 0.8 to 1.11;p = 0.5) Overall 
survival was not affected by both combinations. (Bostrom, et al 2003). Results of this meta-
analysis should be taken with caution as they might be significantly biased by different pre-
maintenance induction regimens. This systematic review fulfilled 7 of 11 criteria of the 
AMSTAR tool. 
The third systematic review compared between the various thiopurines (mainly thioguanine 
and metcaptopurine) as maintenance (Escherich, et al).  In a meta-analysis of 3 trials, event-
free survival was similar for the two agents (OR 0.89, 95% CI, 0.78 to 1.03). However in a 
subgroup analysis of males aged<10 years there was a significant benefit for thiogouanine in 
terms of EFS (OR 0.70, 95% CI, 0.58 to 0.84), although this did not result in a significant 
difference in overall survival (OR 0.83, 95% CI, 0.62 to 1.10). It was concluded that 
mercaptopurine, and not thiogouanine, should be the thiopurine drug of choice for 
maintenance. Although this conclusion is valid for pediatric patients, in the absence of data 
in adults this may also be applicable for them. This systematic review fulfilled 5 of 11 
criteria of the AMSTAR tool. 
5.7 What is the role of CNS prophylaxis and is there a “gold-standard” regimen? 
CNS involvement at presentation in adult ALL patients  is estimated as 5% (Lazarus, et al 
2006). Nevertheless, without prophylaxis administration, CNS recurrence occurs in 
approximately 30% of adult patients in complete response (Omura, et al 1980). There are 
several options to administer CNS prophylaxis therapy. These include cranial radiotherapy 
and  intrathecal or intraventricular chemotherapy.  
One pediatric systematic review with individual patient meta-analysis (Clarke, et al 2003) 
reported that prophylactic radiotherapy reduced CNS relapse slightly more than long-term 
intrathecal therapy, however no survival benefit was shown. Also, higher than 21 Gy 
radiation dose did not correlate with lower relapse risk and, the addition of intravenous 
methotrexate to regimens containing either radiation and intrathecal therapy led to a better 
EFS. This systematic review fulfilled 4 of 11 criteria of the AMSTAR tool. 
6. An overview of systematic reviews in supportive care for patients with 
acute leukemia 
Supportive care in acute leukemia has improved dramatically during the last decades and 
contributed to the improved overall survival of AL patients.  
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7. Myeloid growth factors 
The use of G-CSF and GM-CSF results in a dose dependent increase in the levels of 
circulating neutrophils, mainly as a result of shortening the transit time from stem cell to 
mature cells (Griffin 2001). During intensive chemotherapy, acute leukemia patients 
experience prolonged and profound neutropenia, which is a risk factor for bacterial and 
fungal infections, for increased mortality. Patients with acute leukemia can be treated with 
myeloid growth factors as primary or secondary prophylaxis (before or after the 
development of neutropenia, respectively) or for priming (before or concurrent with 
chemotherapy) with the aim of sensitizing blast cells and recruiting them into cell-cycle, 
thus enhancing their susceptibility to cytotxic agents like cytarabine.  
Five systematic reviews assessed the effect of myeloid growth factors in acute leukemia 
patients.  
The first one is a comprehensive systematic review and meta-analysis, published in 2007 by 
Sung et al and comprises 148 RCTs, randomizing 16,839 patients with all types of cancer. 
Patients were randomly assigned to receive chemotherapy with or without prophylaxis with 
myeloid growth factors (Sung, et al 2007). There was no difference between the two groups 
in short term all cause mortality and in infection related mortality. However, the use of 
myeloid-growth factors was associated with reduction of clinically and microbiologically 
documented infections (RR 0.75, 95% CI 0.62 to 0.92, and RR 0.86, 95% CI, 0.77-0.96, 
respectively). Subgroup analysis of  acute leukemia patients did not show any difference in 
short term all cause mortality and infection related mortality, as well (Sung, et al 2007). This 
systematic review fulfilled 9 of 11 criteria of the AMSTAR tool. 
The second systematic review and meta-analysis compared the prophylactic use of G-CSF in 
patients with AML receiving chemotherapy, to placebo/no treatment (control group) 
(Wang, et al 2009a, Wang, et al 2009b). This review included seven trials with almost 2000 
participants, and did not show difference in overall survival between the G-CSF group and 
the control group (Wang, et al 2009a) This systematic review fulfilled 5 of 11 criteria of the 
AMSTAR tool.  
In a systematic review and meta-analysis recently conducted by our group, we questioned 
the role of myeloid growth factors administrated to AML patients concurrent with or post 
chemotherapy (Gurion, et al., 2011). There was no difference in short term and long term all 
cause mortality, CR rate, DFS and relapse rate between the arm receiving growth factors and 
the control arm. Furthermore, the use of myeloid growth factors was not associated with a 
reduction in the incidence of infections. This systematic review fulfilled 10 of the 11 criteria 
of the AMSTAR tool. 
Another recently published systematic review compared the administration of myeloid 
growth factors in AML patients receiving chemotherapy to control/placebo (Heuser, et al 
2011). Among patients receiving primary prophylaxis, time to neutrophil recovery and 
hospitalization stay were shorter, yet no difference was shown in CR, event and DFS and 
overall survival, compared to no prophylaxis. Among patients receiving growth factors for 
priming, there was also no difference in CR, event free and disease free survival overall 
survival. This review fulfilled 7 of 11 criteria of the AMSTAR tool. 
In another meta-analysis, the use of myeloid growth factors for priming did not affect CR 
rate, DFS or overall survival (Sung, et al 2009). Subgroup analyses according to type of 
myeloid growth factors, the timing of administration and patients' age did not affect 
www.intechopen.com
 
Therapeutic Interventions in Acute Leukemia 
 
361 
outcomes. The main limitation of these meta-analyses is their heterogeneity in terms of 
patients’ characteristics, chemotherapy regimens and trial designs.  
To conclude, the main beneficial effects of growth factors are acceleration of neutrophil 
recovery by 2 to 5 days and a reduction in the length of hospitalization.(Griffin 2001, Inoue, 
et al 1990, Lemoli, et al 1991, Lowenberg, et al 1988, Park, et al 1989). With regard to priming 
with growth factors in AML, 2 meta-analyses did not demonstrate a statistical significant 
effect on remission rate and overall survival and therefore do not support their regular use.  
7.2 Prophylactic anti-infectious treatment 
Two systematic review and meta-analyses assessed the effect of antibacterial and antifungal 
prophylaxis in neutropenic patients receiving chemotherapy.  
Gafter-Gvili et al. evaluated the use of antibacterial prophylaxis for afebrile neuropenic 
patients (Gafter-Gvili, et al 2005). The administration of antibacterial prophylaxis reduced 
all-cause mortality by 33% (95% CI 0.55 to 0.81) in neutropenic patients who received any 
antibiotic prophylaxis and by 48% (95% CI 0.35 to 0.77) in patients who received quinolones 
for prophylaxis compared to placebo or no intervention. Also, the occurrence of febrile 
episodes and bacterial infections decreased significantly. This review fulfilled 10 of 11 
criteria of the AMSTAR tool. 
Robenshtock et al. evaluated antifungal agents for prophylaxis in neutropenic patients 
following chemotherapy or after allogeneic HCT (Robenshtok, et al 2007). All-cause 
mortality was reduced significantly in patients receiving antifungal prophylaxis compared 
with placebo, no treatment, or non-systemic antifungals (RR 0.84, 95% CI, 0.74 to 0.95). In a 
subgroup analysis of patients with acute leukemia there was a significant reduction in 
fungal-related mortality and documented invasive fungal infections, yet there was no 
difference in mortality. This review fulfilled 10 of 11 criteria of the AMSTAR tool. 
7.3 Transfusion support 
One systematic review and meta-analysis evaluated the prophylactic use of platelets in 
patients with hematological malignancies(Stanworth, et al 2004). Three studies compared 
prophylactic with therapeutic use of platelets. There was no difference in all-cause 
mortality, or mortality due to hemorrhagic cause. Of note, studies were conducted between 
1974-1982 and were small with marked heterogeneity, thus the results of this meta-analysis 
should be taken with caution. Three prospective studies compared the platelet transfusion 
thresholds of 10 vs. 20x109 /L. There were no statistically significant differences between the 
groups with regards to mortality, remission rates, number of participants with severe 
bleeding events or red cell transfusion requirements. 
The main limitation of this review is the inclusion of a limited number of small studies in 
different three meta-analyses, carrying a potential risk for bias, though no publication bias 
was reported. This review fulfilled 8 of 11 criteria of the AMSTAR tool. 
Recently, two published RCTs compared low dose to high dose prophylactic platelets 
transfusion (Heddle, et al 2009, Slichter, et al). Both showed no difference in grade 2-4 
bleeding incidence between patients allocated to low threshold of platelets administration 
and no difference between different doses of platelet transfusion. However, one of the 
studies was prematurely stopped because of 5.2% grade 4 bleeding in the lower dose 
platelets compared to none in the high dose (Heddle, et al 2009). 
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8. Conclusions 
The progress made in the last 4 decades in the treatment of patients with acute leukemia is 
the consequence of a constant process of testing, data compilation and re-testing. Data 
gathering on a specific question using explicit, preplanned scientific methods to identify 
select and synthesize all relevant studies is the process of systematic review, which provides 
the clinician with the best evidence, and should form the basis for rational medical decision-
making. 
In this chapter we examined the evidence accumulated in various aspects of leukemia 
management, based on RCTs and systematic reviews and meta-analyses.  While in certain 
areas such as the role of tyrosine kinase inhibitors in Philadelphia positive ALL or allogeneic 
transplant in adult patients with ALL a consensus could be reached according to the data 
published so far, many questions are still open in the field of leukemia which warrant 
conduction of further clinical trials. 
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